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Abstract
Deficiencies in mismatch repair (MMR) are associated with carcinogenesis. Rhodium
metalloinsertors bind to DNA base mismatches with high specificity and inhibit cellular proliferation
preferentially in MMR-deficient cells versus MMR-proficient cells. A family of chrysenequinone
diimine complexes of rhodium with varying ancillary ligands that serve as DNA metalloinsertors
has been synthesized, and both DNA mismatch binding affinities and antiproliferative activities
against the human colorectal carcinoma cell lines HCT116N and HCT116O, an isogenic model
system for MMR deficiency, have been determined. DNA photocleavage experiments reveal that all
complexes bind to the mismatch sites with high specificities; DNA binding affinities to
oligonucleotides containing single base CA and CC mismatches, obtained through photocleavage
titration or competition, vary from 104 to 108 M−1 for the series of complexes. Significantly, binding
affinities are found to be inversely related to ancillary ligand size and directly related to differential
inhibition of the HCT116 cell lines. The observed trend in binding affinity is consistent with the
metalloinsertion mode where the complex binds from the minor groove with ejection of mismatched
base pairs. The correlation between binding affinity and targeting of the MMR-deficient cell line
suggests that rhodium metalloinsertors exert their selective biological effects on MMR-deficient cells
through mismatch binding in vivo.
Introduction
The mismatch repair (MMR) pathway corrects single base errors and insertion/deletion loops
that arise during DNA synthesis, increasing the fidelity of DNA replication by a factor of 50–
1000.1 If uncorrected, mismatches are converted to mutations in subsequent cycles of DNA
replication, and cells with MMR deficiencies, not surprisingly, exhibit elevated mutation rates.
2–4 Germline mutations in hMLH1 or hMSH2, essential genes for MMR in humans,
dramatically increase the risk of developing hereditary nonpolyposis colon cancer (HNPCC),
the most common type of inherited colon cancer.5,6 HNPCC is marked by early onset and the
presence of cancers in several other tissue types.6 Roughly 15% of sporadic colorectal cancer
cases have also been linked to MMR deficiency.7 Epigenetic silencing of the MMR genes has
been identified as the cause of MMR deficiency in these cases.8 In addition to colorectal cancer,
mismatch repair deficiencies have been found in approximately 16% of solid tumors of all
tissue types.3,9
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Importantly, MMR deficiency confers resistance or tolerance to many of the anti-cancer agents
currently in clinical use.10,11 Alkylation by the commonly used chemotherapeutic agents N-
methyl-N-nitrosourea (MNU) and N-methyl-N′-nitro-N-nitrosoguanidine (MNNG) at the O6
position of guanine nucleotides triggers an apoptotic response after recognition of O6-meG:C
and O6-meG:T base pairs by the MMR pathway, while MMR-deficient cells tolerate this DNA
methylation.10–12 Failure to recognize DNA adducts is also involved in the resistance of MMR-
deficient cells to the platinum compounds cisplatin and carboplatin.10–13 The incorporation of
anti-metabolites such as 5-fluorouracil and 6-thioguanine into DNA triggers cell cycle arrest
and apoptosis through the MMR pathway, and consequently MMR-deficient cells are resistant
to these agents as well.14,15 Other studies have shown low-level resistance to the type I
topoisomerase poisons camptothecin and topotecan in hMLH1 deficient lines and to the type
II topoisomerase poisons doxorubicin, epirubicin, and mitoxantrone in hMLH1 or hMSH2
deficient lines.16 It has also been hypothesized that treatment regimens with agents such as
cisplatin might enrich tumors for MMR-deficient cells,17 and it has been shown that a
substantial portion of secondary, or therapy-related, leukemias show signs of MMR deficiency.
17,18 Collectively, these results show the broad involvement of MMR in mediating drug
response, the effects of MMR deficiency on this response, and the need to develop therapeutic
agents that specifically target MMR-deficient cells.
Our laboratory has previously developed bulky rhodium complexes that target DNA
mismatches in vitro.19–23 These octahedral complexes contain an expansive tetracyclic
aromatic ligand that can be accommodated preferentially by DNA at a thermodynamically
destabilized mismatch site. The first-generation compound, Rh(bpy)2chrysi3+ (chrysi = 5,6-
chrysenequinone diimine), binds 80% of DNA mismatches with typical binding constants of
106 M−1 and remarkable specificity for mismatched DNA; in a 2.6 kb DNA fragment DNA
photocleavage reveals specific targeting of the mismatch.19,20,23 Subsequent work led to the
incorporation of nitrogen atoms into the intercalating ligand and a 50-fold increase in binding
affinity for the second-generation compound, Rh(bpy)2phzi3+ (phzi = benzo[a]-phenazine-5,6-
quinonediimine).21 A high-resolution crystal structure of Rh(bpy)2chrysi3+ bound to single
AC mismatches within a DNA oligonucleotide duplex reveals a distinctive binding mode at
the mismatched site.24 We had previously determined that tris(chelate) complexes of Rh with
a planar aromatic ligand bind to well-matched DNA by partial intercalation of the planar ligand
from the major groove side into the base pair stack.25 However, binding to the mismatched
site involves instead insertion of the expansive ligand into the DNA duplex from the minor
groove side at the mismatched site with ejection of the mismatched bases out of the DNA stack;
the inserted ligand stacks fully with adjacent base pairs. NMR studies of Rh(bpy)2chrysi3+
bound to an oligonucleotide containing a CC mismatch confirm this metalloinsertion mode for
the complex at mismatched sites in solution.26
The in vivo effects of Rh(bpy)2chrysi3+ and Rh(bpy)2phzi3+ have been characterized in the
isogenic cell lines HCT116N and HCT116O.27 The HCT116 cell line is a colorectal carcinoma
line deficient in the hMLH1 gene. Two derivative cell lines, HCT116N and HCT116O, have
been made through transfection of human chromosome 3 (ch3) and human chromosome 2
(ch2), respectively. The presence of a functional copy of ch3 restores MMR proficiency in the
HCT116N line, while the HCT116O line transfected with ch2 remains MMR deficient.28 The
mismatch recognition compounds developed within our laboratory were shown to selectively
inhibit the proliferation of the repair-deficient HCT116O line.27
Recent work within our laboratory on luminescent ruthenium complexes has also shown that
these tris(chelate) complexes are taken up inside cells through passive diffusion facilitated by
the membrane potential.29 Variations in ancillary ligands have dramatic effects on cellular
uptake, with increased lipophilicity facilitating uptake. Uptake can also be increased through
functionalization with a nuclear localizing peptide.30
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Here we examine the effects of ancillary ligand variation in the Rh(L)2chrysi3+ family on the
ability of these complexes to target DNA mismatches in vitro and in vivo. Importantly, we
establish that the differential inhibition of cellular proliferation in MMR-deficient cells is
correlated with mismatch binding affinity.
Experimental Procedures
Materials
RhCl3 was purchased from Pressure Chemical, Inc. (Pittsburgh, PA). [Rh(NH3)5Cl]Cl2 was
obtained from Strem Chemical, Inc. (Newburyport, MA). 2,2′-Dipyridylamine (HDPA), 4,7-
diphenyl-1,10-phenanthroline (DIP), and Sephadex ion-exchange resin were obtained from
Sigma-Aldrich (St. Louis, MO). Sep-Pak C18 solid-phase extraction cartridges were purchased
from Waters Chemical Co. (Milford, MA). Phosphoramidites were purchased from Glen
Research (Sterling, VA). Media and supplements were purchased from Invitrogen (Carlsbad,
CA). BrdU, antibodies, buffers, and peroxidase substrate were purchased in kit format from
Roche Molecular Biochemicals (Mannheim, Germany). All commercial materials were used
as received.
Oligonucleotide Synthesis
Oligonucleotides were synthesized on an Applied Biosystems 3400 DNA synthesizer using
standard phosphoramidite chemistry. DNA was synthesized with a 5′-dimethoxytrityl (DMT)
protecting group. The oligonucleotides were cleaved from the beads by reaction with
concentrated ammonium hydroxide at 60 °C overnight. The resulting free oligonucleotides
were purified by HPLC using a C18 reverse-phase column (Varian, Inc.) on a Hewlett-Packard
1100 HPLC. The DMT group was removed by reaction with 80% acetic acid for 15 min at
room temperature. The DMT-free oligonucleotides were precipitated with absolute ethanol
and purified again by HPLC. Positive identification of the oligonucleotides and their purity
were confirmed by MALDI-TOF mass spectrometry. Quantification was performed on a
Beckman DU 7400 spectrophotometer using the extinction coefficients at 260 nm (ε260)
estimated for single-stranded DNA.
Synthesis and Characterization of Metal Complexes
Chrysene-5,6-dione, [Rh(bpy)2chrysi]Cl3, and [Rh(phen)2chrysi]Cl3 were prepared according
to previously reported procedures.19,20,31
[Rh(NH3)4chrysi]OTf3
[Rh(NH3)6]OTf3 was prepared as described by Sargeson.32,33 [Rh(NH3)6]OTf3 was reacted
with a limiting amount of chrysene quinone in a 3:1 acetonitrile:water mixture with excess
sodium hydroxide as a catalyst to form [Rh(NH3)4chrysi]OTf3. Acetonitrile was removed in
vacuo, followed by filtration to remove unreacted chrysenequinone. The product was separated
from unreacted [Rh(NH3)6]OTf3 by solid-phase extraction on a C18 cartridge and eluted with
1:1:0.001 acetonitrile:water:TFA. 1H NMR (DMSO-d6, 50 °C, 300 MHz): δ 13.30 (s), 12.32
(s), 8.876 (t, 1H, 7.7 Hz), 8.787 (d, 1H, 7.9 Hz), 8.57–8.51 (m, 2H), 8.358 (dd, 1H, 8.9 Hz, 4.6
Hz), 8.145 (d, 1H, 7.7 Hz), 7.85–7.70 (m, 4H), 4.73–4.54 (broad m, 6H), 3.862 (s, 3H) ppm.
UV/vis (H2O, pH 5): 263 nm (60 900 M−1 cm−1), 283 nm (38 100 M−1 cm−1), 326 nm (12 600
M−1 cm−1), 413 nm (12 000 M−1 cm−1). MALDI-MS (cation): 425 m/z (M − 2H+) obsd, 427
m/z calcd.
rac-[Rh(HDPA)2(chrysi)]OTf3
[Rh(NH3)4(chrysi)]OTf3 (15 mg, 0.02 mmol) was reacted with HDPA (20 mg, 0.12 mmol,
excess) in 20 mL of ethanol and 20 mL of water. The dark red solution was heated under reflux
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for 16 h. The reaction mixture turned reddish brown upon heating. Ethanol was removed under
vacuum, and the resulting solution was filtered to remove any residue. The filtrate was
concentrated on a Sep-Pak C18 cartridge, eluting with 1:1:0.01 acetonitrile:water:TFA,
lyophilized, and purified on an alumina column, eluting with 2% methanol in dichloromethane.
The fractions were collected and dried under vacuum to give an orange-brown solid (8 mg,
39%). 1H NMR (DMSO-d6, 300 MHz): δ 12.84 (s, 1H), 12.34 (s, 1H), 11.78 (s, 1H), 10.32 (d,
1H, 8.7 Hz), 8.63 (d, 1H, 6.9 Hz), 8.40 (d, 1H, 8.4 Hz), 8.31 (d, 1H, 9.3 Hz), 8.14 (m, 2H),
8.07 (d, 1H, 8.7 Hz), 8.04 (d, 1H, 5.4 Hz), 7.94 (m, 4H), 7.77 (m, 5H), 7.58 (m, 2H), 7.48 (d,
1H, 8.1 Hz), 7.41 (d, 1H, 8.4 Hz), 7.32 (s, 1H), 7.14 (m, 2H), 7.04 (t, 1H, 6.8 Hz), 6.98 (t, 1H,
6.9 Hz), 6.81 (t, 1H, 6.5 Hz) ppm. UV/vis (H2O, pH 5): 287 nm (42 200 M−1 cm−1), 321 nm
(23 000 M−1 cm−1), 442 nm (8800 M−1 cm−1). ESI-MS (cation): 699.2 m/z (M − 2H+), 350.1
m/z (M − H2+) obsd, 699.2 m/z (M − 2H+) calcd.
rac-[Rh(DIP)2(NH3)2]OTf3
RhCl3 and 2 equiv of DIP were combined in 1:1 ethanol:water and refluxed overnight. The
solvent was removed in vacuo, and the product was recrystallized by dissolving in acetonitrile
at 60 °C and cooling to −20 °C. The precipitate was collected by filtration, washed in diethyl
ether, and dissolved in neat triflic acid. The solution was again cooled and added dropwise to
NH4OH at −20 °C. The pale white precipitate was collected by filtration and washed with a
small amount of water to give [Rh(DIP)2(NH3)2]OTf3.
rac-[Rh(DIP)2chrysi]Cl3
rac-[Rh(DIP)2(NH3)2]OTf3 was combined with a 10% excess of 5,6-chrysenequinone and a
catalytic amount of NaOH in acetonitrile and stirred at room temperature overnight. The
condensation was terminated by addition of a stoichiometric amount of HCl. The solvent was
removed in vacuo, and the product was purified by alumina column chromatography. Unbound
chrysi ligand eluted first with ethyl acetate, and the purified product then eluted with
acetonitrile. Finally, the compound was dissolved in 3:2 MeCN:H2O, and the triflate counterion
was exchanged for chloride ion with Sephadex QAE-125 ion-exchange resin. UV/vis (H2O,
pH 5): 290 nm (104 000 M−1 cm−1), 335 nm (43 900 M−1 cm−1), 373 nm (22 300 M−1
cm−1). ESI-MS (cation): 1020.9 m/z (M − 2H+), 511.0 m/z (M − H2+) obsd, 1023 m/z (M −
H2+) calcd.
Photocleavage Titrations
The oligonucleotide was 32P-labeled at the 5′-end by incubating DNA with 32P-ATP and
polynucleotide kinase (PNK) at 37 °C for 2 h, followed by purification using gel
electrophoresis. A small amount of the labeled DNA (less than 1% of the total amount of DNA)
was added to 2 μM DNA in 100 mM NaCl, 20 mM NaPi, pH 7.1 buffer. The DNA hairpin was
annealed by heating at 90 °C for 10 min and cooling slowly to room temperature over a period
of 2 h. Racemic rhodium complex solutions ranging from nanomolar to micromolar
concentration were made in Milli-Q water. Annealed 2 μM DNA (10 μL) and 10 μL of Rh
solution at each concentration were mixed in a microcentrifuge tube and incubated at 37 °C
for 10 min. A light control (LC), in which the DNA was mixed with 10 μL of water and
irradiated, and a dark control (DC), in which the DNA was mixed with the highest concentration
of rhodium complex without irradiation, were also prepared. The samples were left in the heat
block and irradiated on an Oriel (Darmstadt, Germany) 1000-W Hg/Xe solar simulator (340–
440 nm) for 5 min. The irradiated samples were dried and electrophoresed in a 20% denaturing
polyacrylamide gel. The gel was then exposed to a phosphor screen, and the relative amounts
of DNA in each band were quantitated by phosphorimagery (ImageQuant).
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Binding Constant Determination
The fraction of DNA cleaved in each lane on the gel was normalized and plotted against the
log of the concentration of rhodium complex. At least three photocleavage titrations were
carried out for each racemic metal complex. The pooled data were fit to a sigmoidal curve
using OriginPro 6.1. The resulting midpoint value (i.e., the log of [rhodium complex] at the
inflection point of the curve) was converted to units of concentration ([Rh50%]). The
dissociation constant was calculated according to KD = [Rh50%] − 0.5[DNA], and the binding
constant was defined as KB = 1/KD. The errors were derived from the errors associated with
the midpoint values. For complexes that did not photocleave DNA, a binding competition
titration was carried out with a constant amount (1 μM) of rac-Rh(bpy)2(chrysi)3+ added to
each sample. The binding and dissociation constants of the non-photocleaving complex were
calculated by solving simultaneous equlibiria involving DNA, Rh(bpy)2(chrysi)3+, and the
complex in question in Mathematica 6.0.
Cell Culture
HCT116N and HCT116O cells were grown in RPMI medium 1640 supplemented with 10%
FBS, 2 mM L-glutamine, 0.1 mM nonessential amino acids, 1 mM sodium pyruvate, 100 units/
mL penicillin, 100 μg/mL streptomycin, and 400 μg/mL Geneticin (G418). Cells were grown
in tissue culture flasks and dishes (Corning Costar, Acton, MA) at 37 °C under 5% CO2
atmosphere.
Cellular Proliferation ELISA
HCT116N and HCT116O cells were plated in 96-well plates at 2000 cells/well and allowed
24 h to adhere. The cells were then incubated with rhodium complexes for the durations
specified. For incubation less than 72 h, the Rh-containing medium was replaced with fresh
medium, and the cells were grown for the remainder of the 72 h period. Cells were labeled
with BrdU 24 h before analysis. The BrdU incorporation was quantified by antibody assay
according to established procedures.34,35 Cellular proliferation was expressed as the ratio of
the amount of BrdU incorporated by the treated cells to that of the untreated cells.
Results
Binding Affinities for Metal Complexes at Single Base Mismatches
The binding constants of the family of Rh(L)2chrysi3+ complexes at a CC and AC mismatch
in a 29-mer DNA hairpin with the sequence 5′-
GGCAGGXATGGCTTTTTGCCATCCCTGCC-3′ (X = C or A, underline denotes the
mismatch) were measured. The hairpin sequence allows cleavage site determination on either
strand around the DNA mismatch site. By irradiating samples of DNA titrated with varying
concentrations of a rhodium complex, a photocleavage titration curve is obtained from which
the binding constant of the rhodium complex is determined. A typical autoradiogram, taken
after electrophoresis through a denaturing gel, of samples in a photocleavage titration with
rac-Rh(bpy)2chrysi3+ at a CC mismatch is shown in Figure 2. The position of the
photocleavage bands indicates that Rh(bpy)2chrysi3+ cleaves one base neighboring the
mismatch site near the 3′-end. For this DNA sequence, we observed cleavage on only one
strand as reported earlier.23 This cleavage pattern is found for both rac-Rh(phen)2chrysi3+ and
rac-Rh(DIP)2chrysi3+ and holds for the AC mismatch for rac-Rh(bpy)2chrysi3+ and rac-Rh
(phen)2chrysi3+. No other photocleavage bands are observed, demonstrating the high
specificity of Rh(L)2chrysi3+ complexes binding to the mismatch. The photocleavage titration
curve is generated from the autoradiogram by quantifying the amount of photocleavage relative
to the total amount of DNA at each Rh concentration. Pooled data from at least three repeats
were fitted to a sigmoidal curve (Figure 2) for determination of the midpoint ([Rh50%]) and
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the dissociation constant (KD). The KD value for rac-Rh(bpy)2chrysi3+ at a CC mismatch is
found to be 30 nM. For rac-Rh(phen)2chrysi3+ and rac-Rh(DIP)2chrysi3+ at a CC mismatch,
KD values of 320 nM and 11 μM are found, respectively (corresponding KB values are shown
in Table 1). For the AC mismatch with both rac-Rh(bpy)2chrysi3+ and rac-Rh
(phen)2chrysi3+, KD values are somewhat higher, as we expect given the greater
thermodynamic stability of an AC mismatch versus a CC mismatch. rac-Rh(DIP)2chrysi3+
does not yield any photocleavage up to 100 μM; thus, its KD value is estimated to be greater
than that.
As with phenanthrenequinone diimine complexes of rhodium containing saturated amine
ligands, Rh(NH3)4 chrysi3+ and rac-Rh(HDPA)2chrysi3+ promote relatively little DNA
cleavage upon irradiation.36 As a result, their binding affinities were determined through
binding competition titrations with 1 μM rac-Rh(bpy)2chrysi3+. On the basis of the binding
constant of Rh(bpy)2chrysi3+, the binding constant of Rh(NH3)4chrysi3+ is calculated by
solving simultaneous equilibria at the inflection point of the photocleavage titration curve.
Through this competitive titration, the binding constant of Rh(NH3)4chrysi3+ at a CC mismatch
is found to be 1.0 × 108 M−1. At an AC mismatch, KB of Rh(NH3)4chrysi3+ is 3.4 × 106
M−1. From similar binding competition titrations, the binding constant of rac-Rh
(HDPA)2chrysi3+ is found to be 2.0 × 107 M−1 at a CC mismatch and 2.6 × 106 M−1 at an AC
mismatch. It is apparent that the binding affinity correlates inversely with complex size; the
smallest complex, Rh(NH3)4chrysi3+, shows the highest affinities for mismatched sites. The
binding constants for the entire series of Rh(L)2chrysi3+ complexes are summarized in Table
1.
Inhibition of Cellular Proliferation by Enzyme-Linked Immunosorbent Assay (ELISA)
An ELISA for DNA synthesis was used to quantify the effects of the metalloinsertors on the
proliferation of HCT116N cells (MMR-proficient) and HCT116O cells (MMR-deficient).27
Both cell lines were incubated with 0–25 μM of each member of the Rh(L)2chrysi3+ family
except Rh(DIP)2chrysi3+, which was administered at 0–5 μM concentrations due to its greater
uptake characteristics. Incubations were performed for 12, 24, 48, or 72 h. After the 12, 24,
and 48 h incubations, the medium containing Rh was replaced with fresh medium, and the cells
were grown for the remainder of the 72 h period. The extent of cellular proliferation is expressed
as the ratio of BrdU incorporated by the rhodium-treated cells as compared to untreated
controls. Figure 3 shows representative data for Rh(NH3)4chrysi3+ at various incubation times.
No significant preferential inhibition of the HCT116O cell line is seen at incubation times less
than 24 h, consistent with previous results for Rh(bpy)2chrysi3+, with the exception of Rh
(DIP)2chrysi3+, which displays a small differential effect at 12 h.27 With longer incubation
times, however, Rh(NH3)4chrysi3+ displays a strong differential effect with preferential
inhibition of the MMR-deficient HCT116O cell line over the MMR-proficient HCT116N cell
line. In particular, 48 h treatment with 10 μM Rh(NH3)4chrysi3+ inhibits the proliferation of
the HCT116O line by 82 ± 2% while exerting little to no effect on the HCT116N line (7 ± 6%
inhibition).
Figure 4 shows the ELISA results for members of the metalloinsertor family as a function of
incubation time. We have shown previously that the Λ-enantiomer of Rh(bpy)2chrysi3+ is
biologically inactive27 and that structurally binding to a mismatch site is enantiospecific for
the Δ-isomer.24 For this reason, treatment with the 10 μM achiral tetraammine complex was
compared to treatment with 20 μM racemic mixtures of the Rh(L)2chrysi3+ complexes (L =
HDPA, bpy, or phen). The differential effect of rhodium treatment between the cells lines was
quantified by subtracting the normalized percentages of cellular proliferation for each cell line.
Notably, the optimal incubation time for each compound is inversely related to the
hydrophobicity of the ancillary ligands, with rac-Rh(phen)2chrysi3+ exhibiting an optimal
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incubation time of 24 h. This trend also continues with rac-Rh(DIP)2chrysi3+, which exhibits
differential effects in as little as 12 h at concentrations as low as 2 μM (Figure 5). Based on the
early effect at 12 h, the HDPA complex may have different uptake characteristics; the
analogous Ru complex has not yet been examined using flow cytometry. With the exception
of the HDPA complex, this variation in activity with incubation time for the family of
complexes parallels closely results seen earlier for uptake in HeLa cells by Ru(bpy)2dppz2+,
Ru(phen)2dppz2+, and Ru(DIP)2dppz2+, where the most rapid uptake is apparent with the
lipophilic DIP complex.29
Figure 6 summarizes the differential effects on cell proliferation and the incubation time for
the family of complexes. Clear correlations with the binding constants for these complexes are
evident (Table 1). Significantly, the differential effect in inhibiting cell proliferation in MMR-
deficient cells is directly correlated to the binding affinity of the compound for DNA
mismatches. Rh(NH3)4chrysi3+ (KB = 1 × 108 M−1 at a CC mismatch), for example, shows the
largest differential effect in inhibiting proliferation of MMR-deficient versus -proficient
HCT116 cells after 72 h (79 ± 5%), while Rh(phen)2chrysi3+ (KB = 3.2 × 106 M−1 at a CC
mismatch) shows a small differential effect (17 ± 7%). The DIP complex is rapidly taken up
by the cells but also shows only a small differential inhibitory effect correlating with its poor
specific binding at the mismatch site.
Discussion
A clear trend emerges when comparing the binding constants of the series of rhodium
complexes to mismatched sites: the DNA mismatch binding affinity increases as the size of
the ancillary ligand decreases. This trend is consistent with what we have learned from the
structural studies, specifically that mismatch binding by insertion via the minor groove is
subject to stringent space constraints. With major groove intercalation, the base rise is increased
and the major groove offers space to accommodate the ancillary ligands. In contrast, with
insertion, there is no increase in base pair rise; the mismatched bases are instead ejected and
replaced by the deeply inserted chrysi ligand. Moreover, the minor groove, small even for
hydrophobic groove binding molecules, offers little space for the ancillary ligands. While little
enantioselectivity is apparent for intercalation of bpy complexes into B-form DNA, Δ-Rh
(bpy)2chrysi3+ binds enantiospecifically to single base mismatches.24,37 Thus steric
interactions of the ancillary ligands are seen as an extremely important factor governing the
binding affinity of a metal complex at the mismatch site.
We have previously demonstrated that mismatch binding affinity is correlated with
thermodynamic destabilization over all mismatch identities and sequence contexts.20,23 Here,
we see for all the complexes that binding to the CC mismatch is tighter than binding to the AC
mismatch. This is consistent with our previous observations, since AC is the
thermodynamically more stable mismatch and, in this case, is estimated to stabilize the hairpin
duplex by ∼0.5 kcal/mol relative to one containing a CC mismatch.38 We assume, then, that
the general trend holds for all members of this metalloinsertor family. This stabilization is
translated into a higher dissociation constant (smaller binding affinity) for the entire series of
rhodium complexes. This decrease in binding affinity depends upon the greater energy required
to eject the mismatched bases from the base pair stack, as evident crystallographically and by
NMR.24,26 Nonetheless, for the family of chrysi complexes, the inverse relationship between
the size of the ancillary ligand and the binding affinity still holds, with the smallest complex
Rh(NH3)4chrysi3+ showing the highest affinity and that of the largest complex, Rh
(DIP)2chrysi3+, more than 2 orders of magnitude lower.
Figure 7 compares the crystal structure of Δ-Rh(bpy)2chrysi3+ bound to the mismatch site24
with models of Δ-Rh(DIP)2chrysi3+ and Rh(NH3)4chrysi3+ similarly bound via the minor
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groove through metalloinsertion. Preserving the DNA conformation from the crystal structure,
we see that Δ-Rh(DIP)2chrysi3+ runs into substantial steric hindrance, as its axial phenyl rings
extend up and down into the groove, directly clashing with the bases. However, its equatorial
phenyl rings do not pose any steric problems, as they point away from the DNA. These
observations are supported by the small binding constant measured for Rh(DIP)2chrysi3+. Rh
(phen)2chrysi3+, intermediate in size, shows binding affinities for the mismatches that are an
order of magnitude lower than those of the bpy derivative but more than an order of magnitude
higher than those of the DIP complex. Rh(HDPA)2chrysi3+ is slightly larger in size than the
bpy derivative, but the HDPA ligands are more flexible, and there is an opportunity for
hydrogen bonding; as a result, Rh(bpy)2chrysi3+ and Rh(HDPA)2chrysi3+ have comparable
affinities for the mismatch. Analogously, the large binding constant of Rh(NH3)4chrysi3+ can
be mostly attributed to its small size. Here it is reasonable to suggest that the axial ammines
may also hydrogen bond with the neighboring base pairs to form additional stabilizing
interactions. Nonetheless, as evident in Figure 7, the small cone size of the tetraammine
structure clearly facilitates deep insertion within the minor groove site. In fact, the clear inverse
correlation of binding affinity with ancillary ligand size, and the finding that Rh
(DIP)2chrysi3+, despite its cumbersome size, is able to bind at all to a mismatch site with some
specificity, corroborate our understanding of the driving force and the dynamics of mismatch
recognition: the π-stacking between the inserted chrysi ligand and the adjacent bases provides
the major stabilizing force for binding, and both the metal complex and DNA distort their
conformations to accommodate each other in the bound state.
Importantly, the DNA mismatch binding affinities of the Rh(L)2chrysi3+ family correlate well
with the differential biological effects seen between the repair-proficient HCT116N and repair-
deficient HCT116O cell lines. This correlation supports the hypothesis that DNA mismatches
are the target of rhodium metalloinsertors in vivo. Because of this correlation, we may attribute
the preferential inhibitory effect on MMR-deficient cells to binding of the complexes to DNA
mismatches. Since the MMR-deficient cells contain more mismatches, the tighter binding
complexes would be expected to display a greater inhibitory effect. It should be noted that
finding any inhibitory effect with these complexes was at first surprising, since they bind DNA
noncovalently and might be expected to be readily displaced. Although the mechanism of
inhibition is not yet fully understood, it is likely that protein recognition of the metal-mismatch
complex, perhaps by RNA polymerase or topoisomerase, may generate a covalent protein–
DNA lesion and contribute to the cellular response.
The differential inhibitory effect seen with Rh(HDPA)2chrysi3+ cannot be understood simply
on the basis of binding affinities. Despite having essentially the same mismatch binding affinity
as Rh(bpy)2chrysi3+, the HDPA complex preferentially inhibits the MMR-deficient cell line
almost as well as Rh(NH3)4chrysi3+ with long incubation times; with short times of incubation,
the differential inhibitory effect by Rh(HDPA)2chrysi3+ is greatest. Both the HDPA ligand and
the amine group have the potential to form hydrogen bonds. This hydrogen bonding capability
and flexibility of the ligands might serve to make them more effective inhibitors of any protein–
DNA interactions. Indeed, ruthenium complexes bearing HDPA ligands have been shown to
exhibit DNA binding and cytotoxicity.39
Certainly, as with any pharmaceutical design, cellular uptake must also be considered. In the
case of the HDPA complex, based upon the variations in inhibitory effect with incubation time,
the amine ligands may facilitate nuclear uptake. Dppz analogues with the HDPA ligands have
not yet been examined with respect to their uptake characteristics. For the bpy complexes, the
48 h incubation time required for Rh(bpy)2chrysi3+ to exert its anti-proliferative effect matches
the 48 h requirement observed for Ru(bpy)2dppz2+ uptake in HeLa cells.27,29 The more
lipophilic Rh(DIP)2chrysi3+ here is found to exert anti-proliferative effects at much shorter
incubation times and lower concentrations, which also matches the accelerated uptake observed
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for Ru(DIP)2dppz2+. Cellular uptake is surely a rate-limiting factor in biological activity of the
rhodium metalloinsertors, yet cellular uptake is not the only challenge: proper subcellular
localization must also be achieved in order for any drug to act upon its target. It has been well
established that lipophilic cations preferentially target the mitochondria, whereas hydrophilic
cations do not.40,41 It may be that Rh(HDPA)2chrysi3+ and Rh(NH3)4chrysi3+ lack the
lipophilicity required for mitochondrial accumulation, allowing a greater proportion of these
compounds to reach the nucleus once inside the cell. This difference in intracellular partitioning
could then account for the differential effects of Rh(HDPA)2chrysi3+.
In the development of octahedral rhodium complexes as anti-cancer agents, the choice of
ancillary ligand can be seen as a design tradeoff, with the binding affinity for a DNA mismatch
greatly outweighing uptake properties as the critical factor in the successful targeting of repair-
deficient cells. Beyond their effects on DNA binding and overall cellular uptake, it is highly
likely that the ancillary ligands affect the cellular response in other ways, including the potential
for hydrogen bonding and differences in uptake and intracellular distribution. Here we are
confronted with a tradeoff that may seem inevitable: more hydrophobic ligands facilitate
cellular uptake but impede mismatch binding. Perhaps this tradeoff can be avoided by making
conjugates arranged with functional moieties tethered with consideration of the structure of
the DNA-bound complex associated snugly in the minor groove. Most importantly, these data
support the contention that the cell-specific inhibitory effect we observe depends upon binding
to the DNA mismatch inside the cell. This cell-specific strategy thus represents a promising
direction in the development of small metal complexes that react preferentially in MMR-
deficient cells, those susceptible to cancerous transformation.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1.
Rh(L)2chrysi3+ family of metalloinsertors.
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Figure 2.
Binding affinities determined through DNA photocleavage. The DNA hairpin sequence is 5′-
GGCAGGXATGGCTTTTTGCCATCCCTGCC-3′ (X = C or A, underline denotes the
mismatch). Samples were irradiated and electrophoresed through a 20% denaturing PAGE gel.
A light control (LC, without rhodium) and dark control (DC, without irradiation) were included.
A representative autoradiogram of a photocleavage titration with rac-Rh(bpy)2chrysi3+ (A,
arrows indicate positions of mismatched bases) and a representative sigmoidal curve fit of
pooled data from photocleavage titrations for binding constant determination (B) are shown.
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Figure 3.
Inhibitory effects of Rh(NH3)4chrysi3+ as a function of incubation time on cellular
proliferation. Shown are plots of BrdU incorporation (a measure of DNA synthesis and
therefore cellular proliferation) normalized to the BrdU incorporation of untreated cells as a
function of rhodium concentration. Standard error bars for five trials are shown. MMR-
proficient HCT116N cells (green) and MMR-deficient HCT116O cells (red) were plated and
allowed 24 h to adhere before incubation with 0–25 μM Rh(NH3)4chrysi3+ for 12, 24, 48, or
72 h. At the end of the 12, 24, and 48 h incubations, the medium containing Rh was replaced
with fresh medium for the remainder of the 72 h, followed by ELISA analysis. BrdU was added
to the medium 24 h prior to analysis.
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Figure 4.
Inhibitory effects of rhodium metalloinsertors as a function of incubation time. Shown are plots
of BrdU incorporation normalized to the BrdU incorporation of untreated cells as a function
of rhodium concentration. The inhibition differential is the difference of the normalized
percentages of cellular proliferation for each cell line, with standard error bars (SN–O = √
(SN2 + SO2)). ELISA analyses were performed as in Figure 3. Cells were incubated with no
rhodium, 2 μM rac-Rh(DIP)2chrysi3+, 10 μM Rh(NH3)4chrysi3+, or 20 μM rac-Rh
(L)2chrysi3+ (L = HDPA, bpy, or phen).
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Figure 5.
Inhibitory effects of rac-Rh(DIP)2chrysi3+. Shown are plots of BrdU incorporation normalized
to the BrdU incorporation of untreated cells as a function of rhodium concentration. Standard
error bars for five trials are shown. MMR-proficient HCT116N cells (green) and MMR-
deficient HCT116O cells (red) were plated and allowed 24 h to adhere before incubation with
0–5 μM rac-Rh(DIP)2chrysi3+ for 12 h. At the end of the incubation, the medium containing
Rh was replaced with fresh medium, and cells were grown for an additional 60 h before ELISA
analysis. BrdU was added to the medium 24 h prior to analysis.
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Figure 6.
Inhibitory effects of rhodium metalloinsertors as a function of metal complex identity. Shown
are bar graphs of BrdU incorporation normalized to the BrdU incorporation of untreated cells
as a function of rhodium concentration. The inhibition differential is the difference of the
normalized percentages of cellular proliferation for the two cell lines, HCT116O versus
HCT116N. ELISA analyses were performed as in Figure 3. Cells were incubated with no
rhodium, 2 μM rac-Rh(DIP)2chrysi3+, 10 μM Rh(NH3)4chrysi3+, or 20 μM rac-Rh
(L)2chrysi3+ (L = HDPA, bpy, or phen). A correlation between mismatch binding affinity and
differential inhibition of MMR-deficient cells is evident.
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Figure 7.
Crystal and model structures of rhodium metalloinsertors bound to the mismatch site. Rhodium
insertors (red) are shown bound to the DNA (gray) from the minor groove at the mismatch site
with the bases (adenine in blue, cytosine in yellow) ejected and the chrysi ligand stacked fully
with the adjacent base pairs. The crystal structure of Δ-Rh(bpy)2chrysi3+ bound to the CA
mismatch is shown in panel (A), along with structural models of Δ-Rh(DIP)2chrysi3+ (B) and
Δ-Rh(NH3)4chrysi3+ (C) binding based on the crystal structure. Superposition of the DIP
complex upon the rhodium center of the bpy complex leads to steric clashes with the sugar–
phosphate backbone (possible atoms involved in green), whereas the tetraammine complex is
easily accommodated.
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Table 1
Binding Affinitiesa of Rh(L)2chrysi3+ Complexesb for CC and AC Mismatches
Complex Ancillary ligand KB(CC)/M
-1 KB (AC)/M
-1
Rh(NH3)4chrysi
3+ NH3 1.0 × 10
8 3.4 × 106
Rh(bpy)2chrysi
3+ 3.4 × 107 2.2 × 106
Rh(HDPA)2chrysi
3+ 2.0 × 107 2.6 × 106
Rh(phen)2chrysi
3+ 3.2 × 106 1.4 × 106
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Complex Ancillary ligand KB(CC)/M
-1 KB (AC)/M
-1
Rh(DIP)2chrysi
3+ 9.1 × 104 < 104
a
Uncertainties are estimated to be 10%. Binding constants are determined from photocleavage or binding competition titrations using a DNA hairpin with
the sequence 5′-GGCAGGXATGGCTTTTTGCCATCCCTGCC-3′ (X = C or A, underline denotes the mismatch). Samples were irradiated with a solar
simulator (340–440 nm) at 37 °C in 50 mM NaCl, 10 mM NaPi, pH 7.1, as described in the Experimental Procedures.
b
For the polypyridyl complexes, values are given for racemic mixtures.
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